Builders Earns 2024 Great Place To Work Certification

For a second consecutive year,BuildersearnedCertification™ by Great Place To Work®. The prestigious award is based entirely on what current employees say about their experience working at Builders. This year, 96% of employees agreed that Builders is, in fact, a great place to work – 39 points higher than the average U.S. company. https://mma.prnewswire.com/media/1451994/Builders_Insurance_Group_Logo.jpg Great Place […]

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AMMO, Inc.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In AMMO To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in AMMO between August 19, 2020 and September 24, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi

Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V

Saint Herblain (France) and Schlieren (Zurich), October 16, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Shigella4V (S4V),

October 28, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against VERV

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Verve Therapeutics, Inc. (NASDAQ: VERV). Shareholders who purchased shares of VERV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake

IREN LAWSUIT ALERT: The Gross Law Firm Notifies Iris Energy Limited Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Iris Energy Limited (NASDAQ: IREN). Shareholders who purchased shares of IREN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake

The Gross Law Firm Reminds Elanco Animal Health Incorporated Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 6, 2024 – ELAN

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Elanco Animal Health Incorporated (NYSE: ELAN). Shareholders who purchased shares of ELAN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to

Class Action Filed Against GitLab Inc. (GTLB) – November 4, 2024 Deadline to Join – Contact The Gross Law Firm

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of GitLab Inc. (NASDAQ: GTLB). Shareholders who purchased shares of GTLB during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in

Acclaimed New Book Strives to Teach Investors the Surest Way to Avoid a Fate Faced by Millions: Running Out of Money in Retirement

Author from Sparks Financial Group reveals how a simple, sound mathematical formula provides the foundation for a more successful and reliable retirement income strategy Time after time, hardworking Americans who think they’ve saved plenty of money for retirement get a shocking wake-up call when they realize their nest egg has shrunk dramatically. In most cases,

The Gross Law Firm Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 – SAGE

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Sage Therapeutics, Inc. (NASDAQ: SAGE). Shareholders who purchased shares of SAGE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake

Scroll to Top